Dr. Mannick is a leading expert in the mTOR and geroscience fields and has over 15 years of drug development expertise. She has led mTOR inhibitor clinical development programs both as the Co-Founder and Chief Medical Officer of resTORbio, now Adicet Bio, and as an Executive Director of the New Indications Discovery Unit at the Novartis Institutes of Biomedical Research. She previously served as Head of Research and Development at Life Biosciences and was a Medical Director at Genzyme working in multiple therapeutic areas. Prior to Genzyme she served as a faculty member at Harvard Medical School and University of Massachusetts Medical School. She received an A.B. from Harvard College and an M.D. from Harvard Medical School and completed her residency at Brigham and Women's Hospital, followed by an infectious diseases fellowship as part of the Harvard Combined Infectious Diseases Program.

Over her 25-year career Dr. Jennifer Cermak has co-founded and/or taken public numerous biotechnology companies with a specialization in the formation, R&D development strategy and operations of biotechnology companies. She was an Entrepreneur-in-Residence at Longwood Fund, a member of Sirtris’ Executive Management Team, Co-founder, Executive Management Team and Scientific Advisory Board member of Life Biosciences, Co-founder of Flex Pharma and member of GSK’s CEO's Future Strategy group. She received a Ph.D. in Pathology and Laboratory Medicine from Boston University School of Medicine. She completed her postdoctoral fellowship in the Department of Surgery at Harvard Medical School.

Dennis Yamashita is an exceptional drug hunter and medicinal chemist with 30 years in pharmaceutical and biotech drug discovery. Dennis was VP, Medicinal Chemistry at Axial Therapeutics; VP, Drug Discovery at ORIC; and VP, Chemistry at Trevena, a startup founded by Nobel laureate Robert Lefkowitz. At Trevena, he co-invented OLINVYK (oliceridine), an FDA-approved analgesic for the treatment of post surgical pain. Dennis spent 20 years at GSK, most recently leading drug discovery research collaborations with premier academic institutions, as well as internal drug discovery projects in oncology, osteoarthritis, osteoporosis, and immunology disease areas. Dennis has a B.S. in Chemistry from MIT and Ph.D. in Organic Chemistry from Yale. He mentors MIT postdoc scientists and volunteers at the MIT Sandbox, an entrepreneurship program for MIT students that aims to move ideas from concept to societal impacts.